Member Company

Renovia

Renovia is a US-based, women-led developer of prescription digital therapeutics, dedicated to improving the lives of women with pelvic floor disorders by providing accessible and evidence-based solutions.  Renovia’s technology enables non-invasive, drug-free treatment via precise visualization of pelvic floor muscle movement during exercise and tracking of usage and progress, supplemented with coaching and symptom and adherence reporting to prescribers.

Renovia’s flagship product, the leva® Digital Therapeutic, offers a novel, effective, first-line treatment for urinary incontinence (UI), an underreported condition affecting 20 million women in the U.S. alone.  The leva Digital Therapeutic is FDA cleared (K192270) for the treatment of stress, mixed, and mild to moderate urinary incontinence (including overactive bladder), and pelvic floor muscle strengthening in females.

 

Recent research publication/features links:
  1. Peter Rosenblatt, Jessica McKinney, Robert A Rosenberg, Raymon J Iglesias, Robin C Sutherland, Samantha J Pulliam, Evaluation of an accelerometer-based digital health system for the treatment of female urinary incontinence: A pilot study, Neurourol Urodyn. 2019 Sep;38(7):1944-1952. doi: 10.1002/nau.24097. Epub 2019 Jul 16.
  2. Milena M Weinstein, Sarah Collins, Lieschen Quiroz, Jennifer T Anger, Marie Fidela R Paraiso, Jessica DeLong, Holly E Richter, Multicenter Randomized Controlled Trial of Pelvic Floor Muscle Training with a Motion-based Digital Therapeutic Device versus Pelvic Floor Muscle Training Alone for Treatment of Stress-predominant Urinary Incontinence, Female Pelvic Med Reconstr Surg. 2021 Mar 23. doi: 10.1097/SPV.0000000000001052.
  3. Milena M Weinstein, Samantha J Pulliam, Holly E Richter, Randomized trial comparing efficacy of pelvic floor muscle training with a digital therapeutic motion-based device to standard pelvic floor exercises for treatment of stress urinary incontinence (SUV trial): An all-virtual trial design, Contemp Clin Trials. 2021 Apr 16;105:106406. doi: 10.1016/j.cct.2021.106406
Copyright © 2021 Digital Therapeutics Alliance™